| Name | Title | Contact Details |
|---|---|---|
Melissa Cummings |
Executive Vice President, Chief Operating Officer | Profile |
Steven Leist |
Chief Technology Officer | Profile |
Caleb O'Connell |
Chief Information Security Officer | Profile |
Altimmune is a clinical-stage immunotherapeutics company focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of infectious disease.
Engage Therapeutics was founded by Greg Mayes, President and CEO; and Jouko Isojarvi MD, PhD Executive Vice President and Chief Medical Officer. Engage`s founders bring a combination of strong biopharma pedigrees and personal, family connections to epilepsy. Greg’s son has epilepsy, while Jouko has spent his entire career taking care of epilepsy patients as well as developing and commercializing approved treatments for this condition.
Mydecine Innovations Group™ (CSE: MYCO) (OTC: NLBIF) (FSE:0NF) is a life sciences parent company dedicated to the development and production of adaptive pathway medicine, natural health products and digital health solutions. Mydecine`s experienced cross functional teams have the dynamic capabilities to oversee all areas of medicine development including synthesis, genetic research, import/export, delivery system development, clinical trial execution, through to product commercialization and distribution. By leveraging strategic partnerships with scientific, medical, military, and clinical organizations, Mydecine is positioned at the forefront of psychedelic medicine naturally derived from fungi, therapeutic solutions, and fungtional™ mushroom vitality products. Our portfolio of unified companies, including Mydecine Health Sciences, Mindleap Health, and NeuroPharm focus on providing innovative and effective options that can provide millions of people with a healthier quality of life.
Modern Meadow was founded on the belief that customers should not have to choose between performance and sustainability. Additionally, we believe that people should not have to choose between a career that helps them achieve their personal goals and a career with purpose. Achieving both personal and professional goals with purpose is possible at Modern Meadow, and we invite qualified professionals to apply for positions of interest. At the intersection of biotechnology and material science, Modern Meadow designs materials solutions for the way we want the world to perform. We are pioneers of biofabrication, building with biology. This enbables us to harness unique properties of proteins to move the world away from petrochemical and animal-derived inputs, leading a shift to the bioeconomy. Modern Meadow Biofabricated Materials offer the world a new way forward. By introducing a more effective, more responsible, and readily available supply, we are shifting demand away from extractive practices and toward a sustainable bioeconomy. Our team is engaged in exciting work to enable us all to move beyond sustainability to real world impact. Our philosophy and sustainability principles help us stay focused on the most critical environmental issues and challenge us to design our products and systems in the most sustainable manner. But we cannot build a bioeconomy alone. We are partnering with companies, developing bio-based supply chains, and speaking with businesses looking to design for sustainability from the start. Together we can create new coalitions to build out the environmentally conscious alternatives our planet desperately needs.
Effector Therapeutics is a clinical-stage biopharmaceutical company focused on pioneering the discovery and development of a new class of oncology drugs known as selective translation regulators (STRs). Translation is the process in cells whereby information in genetic sequences is used to direct synthesis of proteins. Each of eFFECTOR’s product candidates is designed to act on a single protein that regulates, in a coordinated manner, the expression of multiple functionally related proteins that together drive important biological processes such as immune evasion, stress and inflammatory responses. In cancer, the tightly controlled translation of specific proteins becomes dysregulated, leading to malignancy characterized by uncontrolled growth, immune evasion and metastases. eFFECTOR believes that its therapeutic approach can restore the translational control of processes which tumors have hijacked for their benefit, while preserving normal cell function.